Post-exposure hydroxycloroquine prophylaxis for Covid 19

Phase 3

Recruiting

Conditions: COVID-19.
U07.1

Registration Number: IRCT20130306012728N8

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 500

Inclusion Criteria

All persons 18 years of age and older with a desire to participate in the study (resident of Tabriz), including medical staff or patient companions who have been in contact with an approved person with COVID19 over the past 4 days, and Corona test results using a nasopharyngeal swap sample (RT-PCR) and serum testing of Human SARS-Cov-2 IgG / IgM negative.

Exclusion Criteria

Positive Corona test result
Allergy to Hydroxychloroquine
Retinal disease
History of epilepsy
Known deficiency of glucose-6 phosphate dehydrogenase
Chronic kidney disease known, stage 4 or 5 or under dialysis
Chronic liver failure
Weight <40 kg
Known porphyria
Current use of hydroxychloroquine
History of cardiovascular disease or medication (such as amiodarone, digoxin, etc.)
Recognized cancers
Types of autoimmune diseases
Diabetes
Pregnancy or lactation
Existence of fever and any respiratory illness and other infectious diseases when entering the study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of clinical symptoms of COVID-19 disease (especially pulmonary involvement) among people who are asymptomatic when entering the study. Timepoint: At the beginning of the study and 7, 14 and 21 days after the start of the intervention. Method of measurement: The number of cases with clinical symptoms, especially cases of pulmonary involvement in a period of 21 days among the participants in the studied groups and as needed using CT scan results.

Secondary Outcome Measures

Name	Time	Method
Positive COVID19 test result. Timepoint: At the beginning of the study and 7, 14 and 21 days after the intervention. Method of measurement: As a number of new cases, among the studied groups , using nasopharyngeal swap sample by RT-PCR or serum antibody testing.;Hospitalization. Timepoint: Days 7, 14 and 21. Method of measurement: The results will be reported as the number of participants in each arm who need to be hospitalized with COVID19.;Discontinuation of medication or withdrawal from the study. Timepoint: Days 7, 14 and 21. Method of measurement: Using Checklist.;Death incidence. Timepoint: Days 7, 14 and 21. Method of measurement: with follow up the patients.